Estudo randomizado de fase 2 | Químio-hipertermia intravesical adjuvante não é melhor do que quimioterapia passiva em pacientes com câncer de bexiga sem invasão muscular de risco intermediário.

Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial – European Urology

Comentário no Twitter

No benefit of adjuvant intravesical hyperthermic chemo (CHT) for intermediate-risk non–muscle-invasive bladder cancer
🔸DFS @ 24 mo was 61% vs 60%
🔸Patients treated with CHT were less likely to complete their treatment @EUplatinum @OncoAlert @Uroweb https://t.co/q8lB2MxBFf pic.twitter.com/E8Ay5hirBb

— Yüksel Ürün (@DrYukselUrun) August 22, 2022

Sob  licença de Creative Commons